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Prologue to STRIVE 
• West Africa Ebola outbreak unprecedented in size and 
complexity 
• WHO convened consultation on potential Ebola therapies and 
vaccines (September 2014) 
 
 
“Accelerate [vaccine] development and safe use in 
countries with outbreaks” 
• CDC decided to expand West Africa response to include 
vaccine trial 
STRIVE Overarching Goal and Objectives 
Overarching Goal 
 
 
 
 
To accelerate introduction and use of an Ebola 
prevention vaccine among at-risk people in Sierra Leone 
with concurrent evaluation of the efficacy and safety of 
the vaccine  
Objectves 
• Estimate the efficacy of a single dose of rVSV-ZEBOV 
preventing laboratory-confirmed Ebola virus disease (EVD) 
• Assess serious adverse events (SAE) following administration 
of the vaccine 
• Collect and store serum for baseline seroprevalence  and  
immunogenicity evaluations 
 
 
 
 
 
STRIVE Principal Study Partners 
Sierra Leone 
• College of Medicine and Allied Health Sciences (COMAHS)  
• Ministry of Health and Sanitation (MOHS) 
United States 
• CDC 
• The Biomedical Advanced Research and Development 
Authority (BARDA) 
• Merck/New Link 
The Vaccine: rVSV-ZEBOV 
• Live-attenuated recombinant vesicular stomatitis virus (rVSV) 
vaccine expressing the glycoprotein of Zaire Ebola virus 
(ZEBOV) 
• Developed by Public Health Agency Canada; Merck currently 
holds license 
• Administered as a single dose (2 x 107 pfu/mL) 
• Stored -80oC 
 
Study Design 
• Unblinded, randomized trial 
• Phased enrollment over ~4 months  
• Participants individually randomized to: 
-
-
Immediate group: vaccinated at/within 7 days enrollment 
Deferred group: vaccinated 18-24 weeks after enrollment 
• No placebo – all participants vaccinated by end of study 
• Vaccine efficacy measured by comparing EVD incidence in 
vaccinated and deferred groups 
• Adverse events (AE) assessed by following participants post-
vaccination 
Study Population 
• Adults >18 years old 
• Health care workers (Ebola and non-Ebola facilities)  
• Defined by working in health care setting, not job 
 
 
• Selected Ebola frontline workers 
Physicians 
Nurses 
Health aids 
Laboratorians 
Pharmacists 
“Dressers” 
Cleaners 
Administrators  
Security guards 
Surveillance officers 
Ambulance drivers 
Swabbers 
Burial workers 
Site Selection 
• Sample size considerations – epidemiology early in outbreak 
• Logistical considerations 
-
-
Existing infrastructure/ability to enhance infrastructure 
Buildings, cold chain, roads/transportation 
• Ability to monitor for/ensure standard of care for AEs and EVD 
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STRIVE Study Sites and Enrollment as of Aug 14, 2015 STRIVE Study Sites, Sierra Leone 
Participant Follow-up 
• Monitored for AE, SAE, EVD, pregnancy 
-
-
Vaccinated group – 6 months post-vaccination 
Deferred group – From enrollment until vaccinated; then 6 months  
• Monthly phone calls; home visits if cannot be contacted 
• Evaluation of all SAEs by study physician 
• Surveillance to identify participants with suspect EVD 
admitted to EHC/ETU/hospital isolation units 
 
 
Safety and Immunogenicity Sub-studies 
Safety sub-study 
• Intensive safety and reactogenicity assessment 
• 400+ initial participants (~200 immediate, ~200 deferred) 
• Filled out daily health cards day 1-28 
• Followed-up by phone days 1,3, 7,14, 28 
Immunogenicity sub-study (n~500) 
• In collaboration with Merck 
• Baseline seroprevalence and long-term immunogenicity 
• Specimens drawn at 0 (pre-vax), 1, 6, 12-months post-vax 
• Tested in US by Merck/Focus Diagnostics 
 
High-Level Results* 
• Enrollment complete: 8,680 enrolled (April 9-August 21, 2015) 
• As of Oct 18,  >5,550 participants vaccinated 
-
-
-
-
-
 
Immediate vaccination complete:  4,173 vaccinated 
Deferred vaccination ongoing:  >1,350 vaccinated  
• Deferred vaccination planned to be finished mid-December 
• Safety profile consistent with other published studies 
No safety signals in sub-study 
No vaccine-related SAEs 
8 deaths reported to date; none vaccine-related (estimate 43 deaths 
during study) 
 
* Preliminary data through Oct 18, 2015; data subject to change 
High-Level Results (cont)* 
EVD surveillance 
• 43 participants evaluated for suspected EVD 
• All EVD negative  
• 19 malaria positive (RDT, ICT, smear); 6 additional with 
clinically-dx malaria 
Immunogenicity sub-study 
• Enrollment complete (n=506) 
• 92% follow-up on eligible 1-month blood draws 
• 6-month blood draws commence December 2015 
 
  
* Preliminary data through Oct 18, 2015; data subject to change 
• Interim results from WHO Guinea ring trial published in Lancet 
(July 29, 2015) 
• Cluster-randomized ring vaccination with rVSV-ZEBOV around 
contacts and contacts of contacts of index case 
-
-
-
Immediate vaccination 
Delayed vaccination (21 days after randomization) 
Primary outcome lab-confirmed EVD >10 days after randomization 
• Interim analysis included 90 rings (48 immediate, 42 delayed) 
• Concluded VSV-ZEBOV “might be highly efficacious” and “most 
likely effective at the population level when delivered during 
an EVD outbreak via a ring vaccination strategy” 
• Await publication of final results 
    
 
* Henao-Restrepo AM. Lancet. 2015; 386: 857–866;     Henao-Restrepo AM . BMJ. 2015:351 
WHO Guinea Ring Vaccination Trial 
• Based on interim results from Guinea, WHO ring trial expanded 
into Sierra Leone 
-
-
-
-
-
No randomization - all rings immediately vaccinated 
To date, two rings vaccinated in Sierra Leone 
• Amended STRIVE protocol for early vaccination of deferred 
participants not-yet-vaccinated if considered to be at higher risk 
of exposure to EVD 
• Ebola case reported in STRIVE district  (Sept 2015) 
Treated in primary health unit and ETU, and lived in community where 
enrolled STRIVE participants (deferred, not-yet-vaccinated) worked/lived 
Activated amendment 
Vaccinated early ~100 deferred participants 
STRIVE Mid-course Changes 
STRIVE Mid-course Re-evaluation 
• Changing epi of Ebola in Sierra Leone assessment vaccine 
efficacy unlikely 
• Low incidence EVD; little likelihood of exposure  
-
-
145 reported Ebola cases in Sierra Leone since study commenced* 
Few reported cases in HCWs 
• Expansion of WHO ring trial to Sierra Leone further 
decreased likelihood of exposure 
• STRIVE continues with important safety and immunogenicity 
data 
 
 
* WHO sit rep (April 9 – October 14, 2015) 
Ebola Vaccines in Phase II/III Clinical Trials in West Africa 
rVSV-ZEBOV 
(Merck/NewLink/PHAC) 
 
 
 
 
 
 
 
 
ChAd3-ZEBOV 
(NIAID/GSK) 
Ad26-EBOV/MVA-EBOV 
(J&J/BN) 
Ad5-EBOV vaccine 
(China) 
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Phase ll; HCW, FLW 
Phase II; Comparison
ChAd3 and placebo 
 
Phase lll; Ring vax 
Phase II; HCW, FLW 
 
 
Phase II; Comparison 
rVSV and placebo 
 
Phase I/II 
Adults, adol, children
Includes CMI 
 
 
Phase II 
Adults 
 
 
 
Potential Strategies for Use of Ebola Vaccines 
Outbreak control 
 
 
 
 
 
High-risk groups 
Ring vaccination 
Other? 
 
Health care workers 
Ebola frontline workers 
Lab workers 
Other? 
Is there a role for vaccination around survivors? 
Is there a role for vaccination of the general community? 
Scientific and Regulatory Considerations 
for Use of Ebola Vaccines 
• Long-term protection from vaccination 
-
-
-
-
-
Relevant for vaccinating  HCW/frontline workers/lab staff 
Applies to affected countries and international responders 
• Vaccine use in special populations: children, pregnant 
women, HIV-infected persons 
• Use of vaccine for post-exposure prophylaxis 
• Regulatory  
Current use under IND (clinical trial or expanded access) 
EUA(FDA) /EUAL(WHO) increase flexibility and ease of use 
Full licensure most flexible 
Making Decisions about the Use of Ebola Vaccine: 
Ebola Vaccine Advisory Groups 
Global Ebola Vaccine Implementation Team (GEVIT) 
• WHO (lead), CDC, UNICEF, GAVI, Gates 
• Collaborative planning for the introduction of Ebola 
vaccines 
WHO/SAGE 
• Working group on Ebola vaccines and vaccination formed 
Nov 2014 
• Developed framework for use of Ebola vaccines 
• Presented to SAGE (Oct 20, 2015)  
ACIP  
• Future Ebola vaccine working group? 
 
 
STRIVE Successes 
• Providing an opportunity to vaccinate >8,500 health care and 
front line workers; to date have vaccinated >5,550 
• Trained ~400 Sierra Leonean staff  
• Accumulating safety and immunogenicity data for vaccine 
licensure 
• Increasing research and response capacity in country  
• Developing platform for future vaccine and infectious disease 
research 

